Gilead Pays $1.275 Billion Upfront for Hanchen Xingtai's HCXT-2001

On October 22, Gilead licensed HCXT-2001 from Hanchen Xingtai for an upfront payment of $1.275 billion; the drug is in Phase I with no published human data. HCXT-2001 is an oral macrocyclic peptide IL-23 receptor inhibitor with an extended half-life, intended for inflammatory bowel disease (IBD) with potential to expand into psoriasis.